Novo Nordisk A/s

This global phase 3 trial is testing whether a daily pill called etavopivat can reduce the number of painful sickle cell crises in adolescents and adults with sickle cell disease. About 408 participants will be randomly assigned to receive either etavopivat or a placebo for aroun…

This study looks at the long-term safety and effectiveness of etavopivat, an experimental medicine for sickle cell disease and thalassemia. It involves 480 adults, adolescents, and children who have already benefited from etavopivat in a previous study. Participants will continue…

This study is testing the safety of a medicine called eptacog alfa (NovoSeven) for women in India who have severe bleeding after giving birth. 64 women who do not respond to standard treatments will receive one or two doses of the drug. Researchers will monitor for blood clots, a…

This study tests if a new insulin that is injected just once a week works as well as daily insulin shots to control blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly insulin or a standard daily insulin for …

This trial investigates whether an investigational drug called NNC0487-0111, given as a once-weekly injection, can change how much energy the body uses in adults with overweight or obesity. It compares the drug against a low-calorie diet and a placebo, focusing on metabolic rates…

This study tests a new medicine called UBT251, given as a weekly shot, in 300 adults with type 2 diabetes. Some participants will get UBT251, others will get a placebo or an existing drug (semaglutide). The goal is to see if UBT251 can safely lower blood sugar and help with weigh…

This study tests a new once-weekly injection called NNC0662-0419 in 270 adults with type 2 diabetes. It compares the drug against a placebo and an approved medication, semaglutide, to see how well it controls blood sugar and promotes weight loss. The trial is currently recruiting…

This study tests an experimental oral medicine called Inno8 in 30 adults with hemophilia A. The goal is to see if it is safe and how the body processes it. Participants will take multiple doses over about 11 weeks. If successful, Inno8 could offer a more convenient way to control…

This study tests a new medicine called CDR132L in 200 people with a type of heart failure where the heart is stiff and thickened. The goal is to see if it can improve heart structure and function. Participants will receive either the study drug or a placebo by chance, and the stu…

This study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who use a breathing device. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Partic…

This study tests a once-weekly injection called NNC0487-0111 in 630 adults who are overweight or obese and have type 2 diabetes. Participants receive either the active drug or a placebo for about a year. The main goal is to see how much weight they lose, with additional checks on…

This Phase 3 study tests whether a new drug called CagriSema helps people with severe obesity (with or without type 2 diabetes) lose more weight than the existing drug semaglutide. About 2,500 participants will receive either CagriSema or semaglutide for 83 weeks. The main goal i…

This study tests an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults will receive either the drug or a placebo by IV, alongside their usual heart trea…

This early-stage study tests a new medicine (NNC9733-0001) to see if it is safe and tolerable in healthy volunteers and people with type 2 diabetes. Participants receive either the study drug or a placebo as a single injection. The goal is to check for side effects and how the dr…

This study tests two drugs, cagrilintide and semaglutide (alone or together as CagriSema), to help children and adolescents with overweight or obesity lose weight. About 460 participants will receive either the drugs or a placebo for up to 5 years. The main goal is to see how muc…

This study tests a new medicine called NNC0487-0111 in about 5,600 people who have both heart failure and obesity. Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug reduces the risk of heart failure worsening, hospitalization,…

This study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who do not use a CPAP machine. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Par…

This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The stu…

This study tests whether a new medicine called NNC0487-0111, given as a weekly injection, is safe and effective for weight loss in adults with obesity. About 600 participants will receive either the active drug or a placebo (dummy injection) for comparison. The main goal is to me…

This study tests a new drug called NNC0487-0111, given as a once-weekly injection, to see if it helps people with obesity lose weight safely. About 1,150 adults who have tried to lose weight before will receive either the drug or a placebo. The main goal is to measure how much bo…

This study tests Mim8, a drug that helps blood clot by mimicking a missing protein, in people with hemophilia A (with or without inhibitors). Over 450 participants will receive injections for up to 5.5 years to see if it safely prevents bleeding episodes. The goal is to provide a…

This study follows 630 people with type 1 diabetes in Japan who are already prescribed Awiqli, a once-weekly injection. Researchers will track side effects and blood sugar control over one year to see how the drug works in everyday life. The goal is to manage diabetes, not cure i…

This study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …

This study tests two versions of the experimental drug cagrilintide in 234 adults with overweight or obesity. Participants receive either version D or version B by injection once a week for about 6 months. The goal is to see how the drug is processed in the body, not to measure w…

This early-stage trial is testing a new experimental medicine called NNC1679-0001 for type 2 diabetes. Researchers want to see if it is safe and how well the body tolerates it. The study includes both healthy volunteers and people with type 2 diabetes, who will receive either a s…

This program provides concizumab, a daily injection under the skin, for free to people with congenital hemophilia who need better treatment. Participants will be monitored for safety and how well the medicine works over several years. The program is for those with severe hemophil…

This early-stage trial tests a new drug called NNC0497-0040 in healthy people, those with overweight or obesity, and people with type 1 diabetes who are also overweight. The goal is to see if the drug is safe and tolerable when given as a weekly injection. About 146 participants …

This study examines weight loss in adults who took semaglutide (a prescription weight management drug) as part of their routine care. Researchers will analyze medical records from about 35,000 people with overweight or obesity to see how much weight they lost and whether they ach…

This Phase 1 study looks at how CagriSema, semaglutide, and cagrilintide affect muscle health in 100 adults aged 50-70 with obesity and slightly high blood sugar. Participants will receive one of the drugs or a placebo for up to 15 months. The main goal is to measure how well mus…

This early-stage study tests how a new medicine, NNC0487-0111, affects insulin sensitivity and pancreas function in adults with type 2 diabetes. About 80 participants will receive either the study drug or a placebo. The goal is to see if the drug can help the body use insulin bet…

This study tests whether UBT251 is safe and effective for people who are overweight or have obesity. About 333 participants will receive either UBT251 or a placebo injection. The main goals are to check for side effects and measure weight change over time.

This study tests a new monthly injection called ziltivekimab in 10,000 people who recently had a heart attack. The goal is to see if it can lower the risk of having another heart attack, a stroke, or dying from heart disease. Participants will receive either the study drug or a p…

This early study tests a drug called coramitug in 14 people with ATTR-CM, a heart condition caused by abnormal protein buildup. The drug is designed to bind to and help remove these protein clumps from the heart. Researchers will use special scans to see where the drug goes and w…

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the…

This study tests whether a new medicine called ziltivekimab can reduce fatty plaque buildup in heart arteries after a heart attack. About 332 participants will receive either the drug or a placebo for 15 months. The goal is to see if the drug helps control artery disease and prev…

This study tests a potential new medicine called CDR132L in 200 people with heart failure and an enlarged heart. Participants receive either CDR132L or a placebo by IV every 4 weeks for 48 weeks. The goal is to see if the drug can improve heart structure and function.

This study tests a new medicine called NNC0519-0130, given as a weekly injection, in 465 people with chronic kidney disease, with or without type 2 diabetes, who are also overweight or have obesity. The goal is to see if it can improve kidney function and how safe it is compared …

This study tests a new medicine called NNC4005-0001 to see if it is safe and tolerable for people with extra body weight and too much fat in the liver. About 60 adults will get either the medicine or a placebo (a dummy pill) just once. The study lasts about 7 to 8 months and focu…

This study compares the experimental drug CagriSema (cagrilintide and semaglutide) to a calorie-reduced diet in 80 adults with obesity. It measures how each approach changes the body's energy use, like sleeping metabolic rate. The study lasts about 1.5 years, and all participants…

This study tests an experimental drug called NNC4004-0002 in 60 adults with high uric acid but no symptoms. Participants receive either the drug or a placebo as a single injection under the skin. The main goal is to check safety and how the body handles the drug, with a secondary…

This early-stage study tests whether a new drug called NNC0113-5840 is safe for people with overweight or obesity. About 48 adults aged 18-55 with a BMI between 25 and 35 will receive either the drug or a placebo. The main goal is to check for side effects and how the drug moves …

This early-stage study tests a new medicine, NNC6989-0001, for safety and tolerability in 96 healthy adults who are overweight or have obesity. Participants receive either the drug or a placebo by chance. The goal is to check for side effects and how the drug moves through the bo…

This Phase 3 study tests a once-weekly injection called NNC0487-0111 in 400 adults who are overweight or obese and have knee osteoarthritis. The goal is to see if it helps with weight loss and reduces knee pain compared to a placebo. Participants receive either the active drug or…

This Phase 3 trial tests whether a once-weekly injection called NNC0487-0111 can help people with overweight or obesity and knee osteoarthritis lose weight and feel less pain. About 400 adults will receive either the drug or a placebo for several weeks. Researchers will measure c…

This study tests whether cagrilintide, a new injectable drug, causes fewer stomach side effects than a placebo in people with obesity who previously quit GLP-1 medications due to nausea, vomiting, or diarrhea. About 114 participants will receive either cagrilintide or a dummy sho…

This study tests a medicine called cagrilintide to see how it affects appetite and how much people eat. About 120 adults with overweight or obesity will receive either the drug or a placebo for around 30 weeks. The goal is to measure changes in total energy intake from meals and …

This early-stage study tests whether a once-weekly injection called NNC0487-0111 can lower how much people with obesity eat and reduce their appetite. About 120 adults will receive either the drug or a placebo for several months. The goal is to see if the treatment changes energy…

This early-stage trial is testing whether combining two experimental weight loss drugs—cagrilintide and a GIP receptor agonist—causes fewer stomach side effects like nausea and vomiting compared to taking cagrilintide alone. About 100 women who are overweight or obese will receiv…

This early-stage trial is testing a new drug called NNC0537-1482 in 36 adults with heart failure. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo by injection, and neither they nor the doctors will …

This study reviews medical records of 400 adults aged 40-70 who were recently diagnosed with type 2 diabetes in five Southeast Asian countries. Researchers will look at health data from before and after diagnosis to understand how heart disease risk is distributed. No new treatme…

This study looks at how long you need to fast and whether temporarily stopping GLP-1 medications (like liraglutide or semaglutide) affects how much food stays in your stomach. It involves 75 people with obesity who are already taking these drugs. The goal is to understand stomach…

This study surveys physicians in China to understand how they diagnose and manage metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. It focuses on whether and how doctors assess liver fibrosis, a key indicator of disease severity. Th…

This early-stage study tests a new drug called CDR132L in 32 healthy adults. Researchers want to see how much of the drug gets into the blood when given as a shot under the skin compared to an IV drip. The goal is to find the best way to give this medicine to people with heart fa…

This early-stage study is testing whether a new weekly injection called NNC0662-0419 changes how the body processes birth control pills and a common painkiller. Researchers will measure drug levels in the blood of 45 women who cannot become pregnant and have overweight or obesity…

This study follows up on people who previously took the experimental drug INV-347 for obesity. Researchers will monitor their health and measure how much of the drug remains in their blood over time. No new drug is given. The goal is to ensure the drug is safe in the long run.